3Whidey R J, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children. Pediatr infect Dis J,2001,20:127-133.
4Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of oral neuraminidase inhibitotor osehamivir in treating acute influenza. JAMA, 2000,283 : 1061-1065.
5He G, Massarella J, Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its activem etabolite Ro 64-0802. Clin pharmacokinet, 1999,37:471-474.
6Massarella J, He G, Dorr A, et al. The pharmacokinetics and tolerability of the oral neuraminidase inhibitor osehamivir ( RO64-0796/GS4104 ) in healthy adult and elderly volunteers. J Clin Pharmacol, 2000,40:836- 839.
7Hayden FG, Treanor JJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor osehamivir in experimental human influenza, randomized controlled trials for prevevtion and treatment. JAMA, 1999,282: 1240- 1246.
8Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacyand safety of osehamivir in treatment of acute influenza: arandomised contrdled trial. Lancet, 2000,355 : 1845 - 1848.
9Nila JD, Larisa V, Gubareva, et al. Infections with oseltamivir-Resistant influenza A( H1N1 ) virus in the United States. JAMA,2009,301:1034- 1041.
4[2]Zambon M, Hays J,Webster A, et al. Diagnosis of Influenza in the community - relationship of clinical Diagnosis to confirmed virological, serologic, or molecular detection of influenza. Arch Intern Med, 2001, 161: 2116～2122.
5[5]Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza. JAMA, 2000, 283(8):1016～1024.
6Treanor J J, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza[J]. JAMA ,2000,283: 1016-1024.
7Whitley R J, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children[J]. Pediatr lnfee Dis J,2001;20:127-133.
8Nicholson KG,Aoki FY, Osterhaus AD,et al. Efficacy and safety of the oseltamivir in the treatment of acute influenza: a randomized controlled trial[J]. Lancet,2000,355: 1845-1850.
9Kaiser L,Wat C, Mills T,et al. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations [J]. Arch Intern Med ,2003,163: 1667-1672.
10Hayden FG, Treanor J J, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment [J]. JAMA, 1999,282: 1240-1246.
